Gut bacteria study in DLBCL patients on Glofitamab
Part of Cancer, Digestive system clinical trials.
This study looks at the gut microbiome (the bacteria living in your digestive system) in people with a type of lymphoma called DLBCL who are being treated with a drug called Glofitamab. It may help doctors understand how these bacteria affect treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with DLBCL (a type of lymphoma).
- You are planning to receive the drug Glofitamab as part of your treatment.
- You are able to sign a consent form agreeing to take part.
- You do not have any major health problems that are not under control.
- You do not have another cancer besides DLBCL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This study looks at how well glofitamab works in real-world patients with a type of lymphoma that has come back or not responded to treatment. It includes adults who have already received obinutuzumab and at least one dose of glofitamab in a special access program.
This study looks at how well a drug called Glofitamab works in Chinese adults with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not gotten better after one round of standard treatment. It will help doctors understand more about its effects in real-world settings.
This study looks at how well the drug glofitamab works and how safe it is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or hasn't gotten better after treatment. It's for adults in China who are either about to start glofitamab or have started it within the past 6 months.
This study looks at the bacteria living in your gut (your gut microbiome) to see if they affect how well lymphoma responds to treatment. It involves collecting stool and blood samples before and during your standard R-CHOP chemotherapy.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.